ReviewAsian journal of andrology
Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use.
Review in Asian journal of andrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.
- Long-term toxicity of cisplatin in germ-cell tumor survivors.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Pooled it
- Trial
- Post-cycle therapy after androgen abuse: a narrative review of mechanisms, evidence, and clinical perspectives.Endocrine connections · 2026Article
- Leptin Receptor b (LEPRb) Mutations Disrupt Hypothalamic Control of the Reproductive Axis.International journal of molecular sciences · 2026Review
- Emerging peptide and neuroendocrine strategies for TRT-induced reproductive suppression and functional male hypogonadism: a narrative review.Frontiers in reproductive health · 2026Review
- Male reproductive health under environmental, pharmacological, and disease influences: a scoping review.Frontiers in endocrinology · 2026Review
- Testosterone replacement therapy and spermatogenesis in reproductive age men.Nature reviews. Urology · 2025Review
- Male Infertility and Reduced Life Expectancy: Epidemiology, Mechanisms, and Clinical Implications.Journal of clinical medicine · 2025Review
- Pandemic of testosterone abuse: Considerations for male fertility.Arab journal of urology · 2025Review
- Sustanon suppresses spermatogenesis and increases cell death.Translational andrology and urology · 2024Article
- Energy metabolism and spermatogenesis.Heliyon · 2024Review
- Implications of lifestyle factors on male reproductive health.JBRA assisted reproduction · 2024Review
- Management Outcomes in Males With Hypogonadotropic Hypogonadism Treated With Gonadotropins.Cureus · 2023Article
- Review
- New perspectives in functional hypogonadotropic hypogonadism: beyond late onset hypogonadism.Frontiers in endocrinology · 2023Review
- Androgenic-anabolic steroid abuse trend and management: A prospective, cross-sectional, questionnaire-based survey.Health science reports · 2023Article
- Anabolic androgenic steroids and cardiomyopathy: an update.Frontiers in cardiovascular medicine · 2023Review
- An update on male infertility and intratesticular testosterone-insight into novel serum biomarkers.International journal of impotence research · 2022Review
- [Impact of lifestyle and environmental factors on male reproductive health].Urologie (Heidelberg, Germany) · 2022Review
- The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health.International journal of molecular sciences · 2022Review
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of testosterone replacement therapy (TRT) for hypogonadism continues to rise, particularly in younger men who may wish to remain fertile. Concurrently, awareness of a more pervasive use of anabolic-androgenic steroids (AAS) within the general population has been appreciated. Both TRT and AAS can suppress the hypothalamic-pituitary-gonadal (HPG) axis resulting in diminution of spermatogenesis. Therefore, it is important that clinicians recognize previous TRT or AAS use in patients presenting for infertility treatment. Cessation of TRT or AAS use may result in spontaneous recovery of normal spermatogenesis in a reasonable number of patients if allowed sufficient time for recovery. However, some patients may not recover normal spermatogenesis or tolerate waiting for spontaneous recovery. In such cases, clinicians must be aware of the pathophysiologic derangements of the HPG axis related to TRT or AAS use and the pharmacologic agents available to reverse them. The available agents include injectable gonadotropins, selective estrogen receptor modulators, and aromatase inhibitors, but their off-label use is poorly described in the literature, potentially creating a knowledge gap for the clinician. Reviewing their use clinically for the treatment of hypogonadotropic hypogonadism and other HPG axis abnormalities can familiarize the clinician with the manner in which they can be used to recover spermatogenesis after TRT or AAS use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.